365 related articles for article (PubMed ID: 31382410)
21. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
Pobbati AV; Hong W
Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
[TBL] [Abstract][Full Text] [Related]
22. The Hippo Pathway in Prostate Cancer.
Salem O; Hansen CG
Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
[TBL] [Abstract][Full Text] [Related]
23. Role of the Ror family receptors in Wnt5a signaling.
Kamizaki K; Minami Y; Nishita M
In Vitro Cell Dev Biol Anim; 2024 May; 60(5):489-501. PubMed ID: 38587578
[TBL] [Abstract][Full Text] [Related]
24. YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer.
Noguchi S; Saito A; Nagase T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463366
[TBL] [Abstract][Full Text] [Related]
25. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
[TBL] [Abstract][Full Text] [Related]
26. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Rassenti L; Widhopf GF; Yu J; Kipps TJ
Leukemia; 2019 Mar; 33(3):653-661. PubMed ID: 30568170
[TBL] [Abstract][Full Text] [Related]
27. Ror family receptor tyrosine kinases regulate the maintenance of neural progenitor cells in the developing neocortex.
Endo M; Doi R; Nishita M; Minami Y
J Cell Sci; 2012 Apr; 125(Pt 8):2017-29. PubMed ID: 22328498
[TBL] [Abstract][Full Text] [Related]
28. WIP Drives Tumor Progression through YAP/TAZ-Dependent Autonomous Cell Growth.
Gargini R; Escoll M; García E; García-Escudero R; Wandosell F; Antón IM
Cell Rep; 2016 Nov; 17(8):1962-1977. PubMed ID: 27851961
[TBL] [Abstract][Full Text] [Related]
29. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
[TBL] [Abstract][Full Text] [Related]
30. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
[TBL] [Abstract][Full Text] [Related]
31. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
32. Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway.
Hasan K; Kipps TJ
Oncotarget; 2023 Mar; 14():207-209. PubMed ID: 36944183
[No Abstract] [Full Text] [Related]
33. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
34. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
35. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications.
Maugeri-Saccà M; Barba M; Pizzuti L; Vici P; Di Lauro L; Dattilo R; Vitale I; Bartucci M; Mottolese M; De Maria R
Expert Rev Mol Med; 2015 Jul; 17():e14. PubMed ID: 26136233
[TBL] [Abstract][Full Text] [Related]
36. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
37. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
[TBL] [Abstract][Full Text] [Related]
38. Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
Khanal P; Yeung B; Zhao Y; Yang X
Sci Rep; 2019 Apr; 9(1):6394. PubMed ID: 31015482
[TBL] [Abstract][Full Text] [Related]
39. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
Nagashima S; Bao Y; Hata Y
Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
[TBL] [Abstract][Full Text] [Related]
40. An Autocrine Wnt5a Loop Promotes NF-κB Pathway Activation and Cytokine/Chemokine Secretion in Melanoma.
Barbero G; Castro MV; Villanueva MB; Quezada MJ; Fernández NB; DeMorrow S; Lopez-Bergami P
Cells; 2019 Sep; 8(9):. PubMed ID: 31510045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
